Key terms

About ALIM

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ALIM news

Mar 25 7:44am ET Alimera Sciences initiated with a Buy at Maxim by TipRanks Mar 20 8:09am ET Alimera Sciences reports inducement grants under Nasdaq listing rule by TipRanks Mar 19 8:12am ET Alimera announces first patient randomized in radiation retinopathy trial by TipRanks Mar 08 12:25pm ET Buy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical Trials by TipRanks Mar 08 12:17pm ET Alimera Sciences price target raised to $6 from $5 at H.C. Wainwright by TipRanks Mar 07 8:40am ET Analysts Are Bullish on Top Healthcare Stocks: Alimera (ALIM), Avid Bioservices (CDMO) by TipRanks Mar 07 7:32am ET Alimera Sciences reports Q4 EPS (7c) vs (54c) last year by TipRanks Feb 10 4:53am ET Alimera Sciences Launches 2024 Equity Inducement Plan by TipRanks Feb 09 6:16am ET Buy Rating for Alimera’s Stock Amid Favorable NICE Guidance and Promising Clinical Trials by TipRanks Feb 08 8:05am ET Alimera announces NICE issued Final Draft Guidance on ILUVIEN by TipRanks Jan 04 8:18am ET Alimera Sciences completes recruitment for the Synchronicity Study by TipRanks Jan 03 9:05am ET Alimera (ALIM) Receives a Buy from Craig-Hallum by TipRanks Jan 02 8:13am ET Alimera Sciences names Maltz as Chief Financial Officer by TipRanks

No recent news articles are available for ALIM

Aug 08 5:15am ET Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline by NewsFile

ALIM Financials

1-year income & revenue

Key terms

ALIM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ALIM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel
JPMorgan beat earnings expectations this Friday, unofficially kicking off the first quarter earnings season.
Win McNamee/Getty Images
Jamie Dimon says chance of a bad economy is ‘higher than other people think’